Skip to main content
Erschienen in: Supportive Care in Cancer 12/2007

01.12.2007 | Short Communication

Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia

verfasst von: Piet Dirix, Sandra Nuyts, Vincent Vander Poorten, Pierre Delaere, Walter Van den Bogaert

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Xerostomia is a common complication of radiotherapy for head and neck cancer. Symptomatic treatment consists of stringent oral hygiene to prevent oral infections and saliva substitutes to increase comfort. The aim of the study was to evaluate the clinical effectiveness of the BioXtra (BX) dry mouth care system.

Materials and methods

A xerostomia questionnaire consisting of 3 parts (xerostomia symptom score, quality of life (QoL) survey and visual analogue scale (VAS)) was completed by 34 patients suffering from radiation-induced xerostomia, before and after 4 weeks of treatment with the BioXtra moisturizing gel, toothpaste and mouthwash.

Results

The BioXtra products significantly diminished the most common symptoms of xerostomia. Mean VAS score at the start of treatment was 59.8. After treatment, this decreased to 36.4 (p < 0.001). Twenty-six patients (77%) responded to treatment, 11 of these patients (32%) reported a major improvement. Quality of life significantly improved under treatment: mean QoL score at the start was 59.4; this increased to 70.5 (p < 0.001). None of the 34 patients reported any adverse effects and all but 1 patient found the BX dry mouth care system easy to use.

Conclusions

The results of this study suggest that the BioXtra dry mouth care system is effective in reducing the symptoms of radiation-induced xerostomia and improving the quality of life of xerostomia patients, even if a proportion of the benefit is due to a placebo effect. However, further research is necessary to evaluate the efficacy of BioXtra on oral health.
Literatur
1.
Zurück zum Zitat Duxbury AJ, Thakker NS, Wastell DG (1989) A double-blind cross-over trial of a mucin-containing artificial saliva. Br Dent J 166:115–120PubMedCrossRef Duxbury AJ, Thakker NS, Wastell DG (1989) A double-blind cross-over trial of a mucin-containing artificial saliva. Br Dent J 166:115–120PubMedCrossRef
2.
Zurück zum Zitat Epstein JB, Emerton S, Le ND, Stevenson-Moore P (1999) A double-blind crossover trial of Oral Balance gel and Biotène toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 35:132–137PubMedCrossRef Epstein JB, Emerton S, Le ND, Stevenson-Moore P (1999) A double-blind crossover trial of Oral Balance gel and Biotène toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 35:132–137PubMedCrossRef
3.
Zurück zum Zitat Grötz KA, Genitsariotis S, Vehling D, Al-Nawas B (2003) Long-term oral Candida colonization, mucositis and salivary function after head and neck radiotherapy. Support Care Cancer 11:717–721PubMedCrossRef Grötz KA, Genitsariotis S, Vehling D, Al-Nawas B (2003) Long-term oral Candida colonization, mucositis and salivary function after head and neck radiotherapy. Support Care Cancer 11:717–721PubMedCrossRef
4.
Zurück zum Zitat Guchelaar HJ, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281–288PubMedCrossRef Guchelaar HJ, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281–288PubMedCrossRef
5.
Zurück zum Zitat Herlofson BB, Barkvoll P (1996) Oral mucosal desquamation caused by two toothpaste detergents in an experimental model. Eur J Oral Sci 14:21–26CrossRef Herlofson BB, Barkvoll P (1996) Oral mucosal desquamation caused by two toothpaste detergents in an experimental model. Eur J Oral Sci 14:21–26CrossRef
6.
Zurück zum Zitat Jensen S, Pedersen A, Reibel J, Nauntofte B (2003) Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11:207–225PubMed Jensen S, Pedersen A, Reibel J, Nauntofte B (2003) Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11:207–225PubMed
7.
Zurück zum Zitat Johnson JT, Ferretti GA, Nethery WJ et al (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329:390–395PubMedCrossRef Johnson JT, Ferretti GA, Nethery WJ et al (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329:390–395PubMedCrossRef
8.
Zurück zum Zitat Kielbassa AM, Shohadai SP, Schulte-Monting J (2001) Effect of saliva substitutes on mineral content of demineralised and sound dental enamel. Support Care Cancer 9:40–47PubMedCrossRef Kielbassa AM, Shohadai SP, Schulte-Monting J (2001) Effect of saliva substitutes on mineral content of demineralised and sound dental enamel. Support Care Cancer 9:40–47PubMedCrossRef
9.
Zurück zum Zitat Logemann JA, Smith CH, Pauloski BR et al (2001) Effects of xerostomia on perception and performance of swallow function. Head Neck 23:317–321PubMedCrossRef Logemann JA, Smith CH, Pauloski BR et al (2001) Effects of xerostomia on perception and performance of swallow function. Head Neck 23:317–321PubMedCrossRef
10.
Zurück zum Zitat Logemann JA, Pauloski BR, Rademaker AW et al (2003) Xerostomia: 12-month changes in saliva production and its relationship to perception and performance of swallow function, oral intake and diet after chemoradiation. Head Neck 25:432–437PubMedCrossRef Logemann JA, Pauloski BR, Rademaker AW et al (2003) Xerostomia: 12-month changes in saliva production and its relationship to perception and performance of swallow function, oral intake and diet after chemoradiation. Head Neck 25:432–437PubMedCrossRef
11.
Zurück zum Zitat Maes A, Huygh I, Weltens C, Vandevelde G, Delaere P, Evers G, van den Bogaert W (2002) De gustibus: time scale of loss and recovery of tastes caused by radiotherapy. Radiother Oncol 63(2):195–201PubMedCrossRef Maes A, Huygh I, Weltens C, Vandevelde G, Delaere P, Evers G, van den Bogaert W (2002) De gustibus: time scale of loss and recovery of tastes caused by radiotherapy. Radiother Oncol 63(2):195–201PubMedCrossRef
12.
Zurück zum Zitat McMillan AS, Tsang CSP, Wong MCM, Kam AYL (2006) Efficacy of a novel lubricating system in the management of radiotherapy-related xerostomia. Oral Oncol (in press) McMillan AS, Tsang CSP, Wong MCM, Kam AYL (2006) Efficacy of a novel lubricating system in the management of radiotherapy-related xerostomia. Oral Oncol (in press)
13.
Zurück zum Zitat Momm F, Voegova-Neher NJ, Schulte-Mönting J, Guttenberger R (2005) Different saliva substitutes for treatment of xerostomia following radiotherapy. Strahlenther Onkol 181:231–236PubMedCrossRef Momm F, Voegova-Neher NJ, Schulte-Mönting J, Guttenberger R (2005) Different saliva substitutes for treatment of xerostomia following radiotherapy. Strahlenther Onkol 181:231–236PubMedCrossRef
14.
Zurück zum Zitat Nieuw Amerongen AV, Veerman ECI (2003) Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 11:226–231PubMed Nieuw Amerongen AV, Veerman ECI (2003) Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 11:226–231PubMed
15.
Zurück zum Zitat Olsson H, Axell T (1991) Objective and subjective efficacy of saliva substitutes containing mucin and carboxymethylcellulose. Scand J Dent Res 99:316–319PubMed Olsson H, Axell T (1991) Objective and subjective efficacy of saliva substitutes containing mucin and carboxymethylcellulose. Scand J Dent Res 99:316–319PubMed
16.
Zurück zum Zitat Regelink G, Vissink A, Reintsema H, Nauta JM (1998) Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int 29:383–388PubMed Regelink G, Vissink A, Reintsema H, Nauta JM (1998) Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int 29:383–388PubMed
17.
Zurück zum Zitat s’Gravenmade EJ, Roukema PA, Panders AK (1974) The effect of mucin-containing artificial saliva on severe xerostomia. Int J Oral Surg 3:435–439CrossRef s’Gravenmade EJ, Roukema PA, Panders AK (1974) The effect of mucin-containing artificial saliva on severe xerostomia. Int J Oral Surg 3:435–439CrossRef
18.
Zurück zum Zitat Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care 14:319–326CrossRef Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care 14:319–326CrossRef
19.
Zurück zum Zitat Specht L (2002) Oral complications in the head and neck radiation patient. Introduction and scope of the problem. Support Care Cancer 10:36–39PubMedCrossRef Specht L (2002) Oral complications in the head and neck radiation patient. Introduction and scope of the problem. Support Care Cancer 10:36–39PubMedCrossRef
20.
Zurück zum Zitat Temmel AF, Quint C, Schickinger-Fischer B, Hummel T (2005) Taste function in xerostomia before and after treatment with a saliva substitute containing carboxymethylcellulose. J Otolaryngol 34:116–120PubMedCrossRef Temmel AF, Quint C, Schickinger-Fischer B, Hummel T (2005) Taste function in xerostomia before and after treatment with a saliva substitute containing carboxymethylcellulose. J Otolaryngol 34:116–120PubMedCrossRef
21.
Zurück zum Zitat Visch LL, s’Gravenmade EJ, Schaub RM, Van Putten WL, Vissink A (1986) A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. Int J Oral Maxillofac Surg 15:395–400PubMedCrossRef Visch LL, s’Gravenmade EJ, Schaub RM, Van Putten WL, Vissink A (1986) A double-blind crossover trial of CMC- and mucin-containing saliva substitutes. Int J Oral Maxillofac Surg 15:395–400PubMedCrossRef
22.
Zurück zum Zitat Warde P, Kroll B, O’Sullivan B et al (2000) A phase II study of Biotène in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 8:203–208PubMedCrossRef Warde P, Kroll B, O’Sullivan B et al (2000) A phase II study of Biotène in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 8:203–208PubMedCrossRef
Metadaten
Titel
Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia
verfasst von
Piet Dirix
Sandra Nuyts
Vincent Vander Poorten
Pierre Delaere
Walter Van den Bogaert
Publikationsdatum
01.12.2007
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0210-y

Weitere Artikel der Ausgabe 12/2007

Supportive Care in Cancer 12/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.